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Background: Secreted frizzled-related proteins (SFRPs) are a family of proteins that block the Wnt signaling
pathway and loss of SFRP1 expression is found in breast cancer along with a multitude of other human cancers.
Activated Wnt signaling leads to inappropriate mammary gland development and mammary tumorigenesis in
mice. When SFRP1 is knocked down in immortalized non-malignant mammary epithelial cells, the cells exhibit a
malignant phenotype which resembles the characteristics observed in metastatic breast cancer stem-like cells.
However, the effects of SFRP1 loss on mammary gland development in vivo are yet to be elucidated. The
work described here was initiated to investigate the role of SFRP1 in mammary gland development and whether
SFRP1−/− mice exhibit changes in mammary gland morphology and cell signaling pathways shown to be
associated with SFRP1 loss in vitro.
Results: 10 week old nulliparous SFRP1−/− mammary glands exhibited branching with clear lobulo-alveolar
development, which normally only occurs in hormonally stimulated mid-pregnant wt mammary glands. Explant
cultures of SFRP1−/− mammary glands display increased levels of a well known Wnt signaling target gene, Axin2.
Histomorphologic evaluation of virgin glands revealed that by 10 weeks of age, the duct profile is markedly altered
in SFRP1−/− mice showing a significantly higher density of ducts with distinct alveoli present throughout the
mammary gland, and with focal ductal epithelial hyperplasia. These findings persist as the mice age and are evident
at 23 weeks of age. Changes in gene expression, including c-Myc, TGFβ-2, Wnt4, RANKL, and Rspo2 early in
mammary gland development are consistent with the excessive hyper branching phenotype. Finally, we found that
loss of SFRP1 significantly increases the number of mammary epithelial cells capable of mammosphere formation.
Conclusions: Our study indicates that SFRP1 gene is critical for maintaining proper mammary gland development,
and that reduced levels of SFRP1 results in hyperplastic lesions and its loss may be a critical event in cancer initiation.
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Members of the Wnt family of secreted proteins play cru-
cial roles in the morphogenesis of most organ systems
and regulate cellular proliferation, differentiation, migra-
tion and apoptosis [1-3]. The best characterized Wnt
pathway is the canonical Wnt/β-catenin pathway whereby
β-catenin stimulates the expression of specific target
genes including the c-Myc oncogene. Atypical activation
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reproduction in any medium, provided the orthe genesis of a wide range of human cancers, including
breast cancer [3]. In the murine breast, aberrantly acti-
vated Wnt signaling leads to inappropriate mammary
gland development and mammary tumorigenesis [1].
In addition to embryonic development, Wnt family
members are common regulators of postnatal develop-
ment and of homeostasis in adult tissues, including the
growth and differentiation of the mammary gland [4-6].
The first stage of mammary gland development in mice
is the specification of mammary rudiments, a prenatal
event which occurs around embryonic day 10. The sec-
ond stage of mammary development begins at around 3
weeks of age at the onset of puberty in response to ovar-
ian hormones, resulting in a rapid expansion of the pre-
existing rudimentary ductal tree [7]. Branching ductalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pad and is completed at approximately 10 weeks of age.
During this phase of development, the growing tips of
the ducts form the highly proliferative terminal end buds
(TEBs), which house mammary stem cells [8,9]. The
major changes in morphology and function that are
initiated at the start of pregnancy constitute a third stage
in mammary gland development that is influenced and
regulated by Wnt signaling. Development of the gland at
this stage can be reduced to two principal elements: for-
mation of extensive secondary branches of the ductal
tree, and the appearance of alveolar units that constitute
the secretory apparatus of the gland. Pregnancy de-
pendent hormones normally trigger both of these
aspects of mammary morphogenesis, but both can also
be induced prematurely by ectopic expression of Wnt
proteins in virgin mice [9-12].
Secreted frizzled-related proteins (SFRPs) are a family
of Wnt antagonists which contain a cysteine-rich do-
main that is homologous to the Wnt-binding domain of
frizzled receptor proteins [13]. However, SFRPs do not
contain a transmembrane domain and therefore are
released into the extracellular compartment where they
antagonize Wnt signaling by binding to Wnt ligands and
preventing ligand-receptor interactions and signal trans-
duction [14]. Loss of SFRP1 expression is found in mul-
tiple human cancers including breast cancer [15-17].
When SFRP1 is knocked down in immortalized
non-malignant mammary epithelial cells, the cells (TERT-
siSFRP1) acquire a malignant phenotype characteristically
observed in metastatic breast cancer stem-like cells
[18,19]. The work described here was initiated to investi-
gate the role of SFRP1 in mammary gland development
and whether SFRP1−/− mice exhibit changes in mam-
mary gland morphology and cell signaling pathways
shown to be associated with SFRP1 loss in vitro. Previ-
ously, analysis of 41 different non-skeletal tissues, in-
cluding the mammary gland, in 20 or 40 week old mice
has shown no overt morphologic differences between
SFRP1+/+ and SFRP1−/− animals [20]. However, consider-
ing that mammary gland development occurs around
puberty, we chose to look at the morphological effects
of SFRP1 loss beginning at this critical development
stage, and at an adult stage. The significance of these
studies is considerable because methylation of SFRP1
(resulting in suppression of SFRP1 expression) has been
demonstrated to be an early change in premalignant
breast lesions [21,22].
Results and discussion
SFRP1−/− mice exhibit precocious mammary gland
development
To determine the effect of SFRP1 loss on early mam-
mary gland development, we examined whole mountpreparations of mammary glands from female virgin
SFRP1+/+ and SFRP1−/−mice and compared our findings
with pregnant day 8 (P8) and P15 wt animals (Figure 1).
Differences in the mammary gland morphology could be
detected between SFRP1+/+ and SFRP1−/− mice at early
stages of puberty. At 5 weeks of age, SFRP1+/+ mammary
glands exhibited a branching ductal structure typical of a
virgin female with very few alveoli growing from ter-
minal branches at the end buds of the ducts (Figure 1A).
At higher magnification, the branching ductal structures
displayed a smooth surface with a 1–2 cell lining
(Figure 1B). In contrast, in 5 weeks old SFRP1−/− ani-
mals the mammary gland displayed evidence of nascent
ductal side branching (Figure 1C-D), and at 10 weeks of
age a significantly more complex arborized ductal net-
work was formed as compared to the age-matched
SFRP1+/+ gland (Figure 1E-H). In addition, SFRP1−/−
mammary glands exhibited branching with clear lobulo-
alveolar development (low and high magnification
images, Figure 1G-H), which normally only occurs in
hormonally stimulated mid-pregnant wt mammary
glands (Figure 1I-L). Histomorphologic evaluation of vir-
gin glands revealed that at 5 weeks of age, there is only a
marginal difference in the number of ducts present in
SFRP1−/− animals as compared to SFRP1+/+ animals
(data not shown). By 10 weeks of age the duct profile is
markedly altered in SFRP1−/− mice showing a signifi-
cantly higher density of ducts with distinct alveoli
present throughout the mammary gland (Figure 2), and
with focal ductal epithelial hyperplasia. This pattern of
ductal hyperplasia and precocious alveolar formation
that occurs in the 10 week virgin SFRP1−/− mammary
gland (Figure 2C-D) resembles that of the wt P8 ductal
profile (Figure 2I-J). Moreover, these observations persist
as the SFRP1−/− mice age. While alveoli are suitably still
absent in 23 week virgin SFRP1+/+ animals (Figure 2E-
F), the presence of precocious alveoli remains and even
expands in 23 week virgin SFRP1−/− mice (Figure 2G-H),
with mammary gland proliferation baring resemblance
to wt P15 mice (Figure 2K-L). While mammary glands
have previously been examined in SFRP1+/+ and SFRP1−/−
20 and 40 week old animals [20], the methodology of
mammary gland analysis we employed revealed that
there is a striking difference in morphology between
geneotypes. Our findings of precocious development
and persistent hyperplasia of ducts/lobulo-alveolar units
in SFRP1−/− mice are significant because they suggest
that loss of SFRP1 may contribute to an increase in
breast tumor susceptibility.
Our results are consistent with previous studies show-
ing that upregulation of the Wnt/β-catenin pathway and
activation of β-catenin in mice induces precocious
lobulo-alveolar hyperplasia [10-12]. In particular, Lane
et. al. demonstrated that mammary glands from Wnt-
Figure 1 Comparison of the morphology of 5 wk virgin, 10 wk virgin, pregnant day 8, and pregnant day 15 mammary glands. Whole
mounts of inguinal mammary glands stained with carmine alum from (A-B) 5 wk SFRP1+/+, (C-D) 5wk SFRP1−/−, (E-F) 10 wk SFRP1+/+, (G-H) 10
wk SFRP1−/−, (I-J) wt P8, and (K-L) wt P15 females. (B,D,F,H,J,L) Shown medium magnification (200X) of selection from adjacent low magnification
left panel (40X). Tissue was harvested from and assessed in 6 animals/genotype.
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density of ducts compared to non-transgenic littermates
[11]. This pattern of ductal hyperplasia and precocious
alveolar formation has also been described in MMTV-
Wnt1 mice [9,23]. Moreover, Bradbury et. al. showed
that constitutive expression of Wnt4 in the virgin mam-
mary gland also induces structures with a morphology
similar to that seen in pregnancy [24]. To determine
whether the mammary glands of SFRP1−/− mice have
more responsive Wnt/β-catenin signaling, we exploited
an ex vivo tissue culture assay to survey the expression
of a well known Wnt/β-catenin target gene, Axin2, in re-
sponse to Wnt3a. As shown in Figure 3, both in the ab-
sence and presence of the Wnt3a β-catenin stimulating
ligand, SFRP1−/− mice express higher levels of Axin2
protein (Figure 3 B&D). Taken together, our results sug-
gest that SFRP1 is an essential regulator of normal mam-
mary gland development and likely functions in part by
antagonizing the Wnt/β-catenin signaling pathway.
Genes involved in mammary gland morphogenesis are
overexpressed early in SFRP1−/− mice
We next sought to determine whether there were
changes in gene expression early in development that
might help explain the excessive hyper branchingphenotype observed in 10 week old SFRP1−/− mice.
c-Myc is a well characterized downstream gene of
Wnt/β-catenin signaling that is upregulated in re-
sponse to β-catenin transcriptional activation. Real-time
PCR studies confirmed that c-Myc mRNA levels were sig-
nificantly higher in the mammary gland of SFRP1−/−mice
(Figure 4A). Interestingly c-Myc has been shown to induce
precocious mammary development and transformation
when overexpressed in the mouse mammary gland
[25,26]. In addition, virgin mice overexpressing consti-
tutively active β-catenin express abnormally high levels
of c-Myc mRNA [10].
Transforming growth factor (TGF)-β is a multifunc-
tional cytokine that regulates a variety of physiological
processes and also plays a dual role during mammary
gland development and tumorigenesis. We have shown
that loss of SFRP1 expression in vitro allows mammary
cells to acquire sensitivity to TGF-β signaling [27]. In an
initial screen of genes affected by SFRP1 loss in HMECs
we identified several upregulated genes within the TGF-
β pathway, including the TGF-β2 ligand [27]. The real-
time PCR data presented here demonstrate that SFRP1
loss in vivo also results in significantly increased
mRNA levels of TGF-β2 (Figure 4B). These findings
may in part explain the altered mammary gland
Figure 2 Hematoxylin/eosin-stained sections of 10 wk virgin, 23 wk virgin, pregnant day 8, and pregnant day 15 mammary glands. 5
μm section from (A,B) 10 wk SFRP1+/+ female, (C,D) 10 wk SFRP1−/−female, (E,F) 23 wk SFRP1+/+ female, (G,H) 23 wk SFRP1−/−female, (I,J) wt P8
female, and (K,L) wt P15 female. (A,C,E,G,I,K) Low magnification (40X) images illustrate the significant increase in the number of ducts and alveoli
present in 10 wk virgin SFRP1−/−, 23 wk virgin SFRP1−/−, P8 SFRP1+/+,and P15 SFRP1+/+ when compared with virgin SFRP1+/+ animals. Tissue was
harvested from and assessed in 6 animals/genotype.
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it has been shown that TGF-β2, but not TGF-β1 or
TGF-β3, is critical for lung branching in vivo [28] and
synergizes with Wnt to promote mammary gland
branching in vitro [29].
As discussed previously, overexpression of Wnt1,
Wnt10b, and/or Wnt4 induces mammary gland hyper
branching. Therefore, we wanted to establish whether
these particular Wnt ligands are upregulated in SFRP1−/−
animals. The expression of Wnt1 and Wnt10b was
unaffected by SFRP1 loss (data not shown), however
Wnt4 mRNA levels were significantly elevated in the
mammary gland of SFRP1−/− mice (Figure 4C). Interest-
ingly, Wnt4 is expressed during the period when side-
branching occurs in early to mid-pregnancy [30,31].
Brisken et. al. showed that Wnt4 null mammary glands
were deficient in early lobulo-alveolar mammary out-
growth during pregnancy, and that Wnt4 is an effector
for progesterone-induced mammary growth [32].
Critical to the Wnt4 downstream signaling for branch-
ing morphogenesis is the receptor of activated NF-κB
ligand (RANKL) [33,34]. RANKL was originally charac-
terized for its role in the development, survival, and acti-
vation of osteoclasts during bone remodeling [33].Subsequent studies have shown that RANKL deficient
mice exhibit a significant decrease in parity-induced
mammary alveologenesis which results in a lactational
defect [34]. Furthermore, transgenic overexpression of
RANKL or RANK (RANKL receptor) alone into the
murine mammary gland elicits ductal side branching,
alveologenesis, and mammary hyperplasia [35,36]. Con-
sidering that SFRP1 has been shown to bind to and in-
hibit RANKL mediated action [37], we sought to
determine whether the expression of RANKL is affected
by SFRP1 loss. Indeed, we found that mRNA levels of
RANKL were significantly elevated in the mammary
gland of SFRP1−/− mice (Figure 4D). These data lend
support to the notion that SFRP1 may play a role in
tumor susceptibility since abrogation or accentuation of
RANKL signaling renders the mammary epithelium
markedly resistant or susceptible to mammary tumori-
genesis respectively [36,38]. Since RANKL has a role in
bone remodeling and loss of SFRP1 increases the thick-
ness of the trabecular bones [20], it has been suggested
that SFRP1 inhibitors may be beneficial for the treat-
ment and/or prevention of osteoporosis. However,
SFRP1 inhibitors may not be beneficial to women who
are genetically predisposed or who have pre-malignant
Figure 3 Protein expression analysis of the Axin2 ex vivo.
Mouse mammary gland sections were subjected to
immunohistochemistry and stained for the Wnt target gene, Axin2
(brown chromogen). Representative ducts are shown from explant
mammary gland tissues derived from SFRP1+/+ and SFRP1−/− mice
cultured in control media or media containing an exogenous Wnt
ligand (Wnt3a) to induce Wnt signaling: (A) SFRP1+/+ in control
media, (B) SFRP1−/− in control media, (C) SFRP1+/+ in Wnt3a media,
(D) SFRP1−/− in Wnt3a media. Tissue was harvested from and
assessed in 6 animals/genotype.
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cancer.
R-spondin (RSPO) family proteins activate the canon-
ical WNT signaling pathway by binding to the Wnt
co-receptor LRP6 leading to β-catenin-dependent gene
activation [39-41]. Interestingly, the expression of Rspo2
and other Rspo family members is induced when mouse
mammary tumor virus (MMTV) is inserted into mam-
mary epithelial cells, and these proteins have been asso-
ciated with malignant transformation and tumorigenesis
[42-44]. Loss of Rspo1 hinders the development of the
murine mammary gland leading to lack of side branching
along secondary ducts [45]. At 5 weeks of age in SFRP1-/-
mice, we started observing changes in the expression of
genes involved in branching morphogenesis. Although
we did not see Rspo1 changes at this stage (Figure 4E),
the expression of Rspo2 is significantly elevated
(Figure 4F). Additionally enhanced side branching at 10
wks of age in response to SFRP1 loss is associated with
significantly elevated expression of both Rspo1 and
Rspo2 (data not shown). These findings may partially ex-
plain how SFRP1 loss increases the expression of Wnt4,
through Rspo2 enhancement of the β-catenin-dependentactivity of Wnt4 in murine epithelial cells [46]. Further-
more, the expression pattern of Rspo1 parallels that of
Wnt4 during mammary gland development which indi-
cates that there is functional relationship between these
Wnt signaling proteins [45].
Mammary epithelial cells derived from SFRP1−/− mice
have more mammosphere initiating cells
Ductal outgrowth is driven by TEBs, which are believed
to house a small population of cells that are essential for
mammary gland development, mammary stem cells
(MaSCs) [8,9]. Importantly, MaSCs are capable of regen-
erating all cell-lineages that comprise the murine mam-
mary gland and support for their existence comes from
cell enrichment studies using specific cell surface mar-
kers as well as mammary gland transplantation experi-
ments [47,48]. Similar to stem cells in either the
hematopoietic system or neuronal system, the self-
renewal and differentiation of MaSCs is regulated by
multiple genes and pathways. Several studies have shown
that Wnt/β-catenin signaling is activated in several stem
cell types, including in mammary stem cells. Liu et. al.
demonstrated that transgenic mice with activated Wnt/
β-catenin signaling in the mammary gland have a signifi-
cantly higher stem cell-enriched population compared to
wild type mice [49]. Additionally, the stem cell-enriched
population of cultured primary mammary epithelial cells
was significantly increased when cells were treated with
a Wnt agonist and this effect could be abrogated by the
addition of a Wnt pathway inhibitor [49].
Stem cells and progenitor cells from the human mam-
mary gland are able to grow in an anchorage independ-
ent manner (constituting mammospheres) and have
been shown to express very low levels of SFRP1 [50].
Interestingly, the expression of SFRP1 is up-regulated
when mammospheres are induced to differentiate [50].
Considering the premature branching that occurs in the
SFRP1−/−murine mammary gland and that SFRP1 is a
Wnt signaling antagonist, mammosphere formation cap-
acity was compared between mammary epithelial cells
derived from SFRP1+/+ and SFRP1−/− animals. We found
that loss of SFRP1 significantly increases the number of
mammary epithelial cells capable of mammosphere for-
mation (Figure 5). These data are fully consistent with
previous studies showing that inhibition of SFRP1
increases mammosphere formation [18,19]. Although
mammosphere formation is not a definitive measure of
the stem cell population, the literature has shown that
such a capacity is constantly associated with resolute
in vivo stem cell measures [51-53]. If SFRP1 loss indeed
enhances stem cell number, the increase in mammo-
sphere formation is of importance because stem cells are
thought to play a key role in malignant transformation
of the breast since they are more likely to accumulate
Figure 4 Expression analysis of genes altered in SFRP1−/− animals that may be involved in mammary gland branching. For real-time
PCR analysis of c-Myc, TGF-β2, Wnt4, RANKL, Rspo1, and Rspo2 gene expression, total RNA was isolated from the mammary glands of 5wk virgin
SFRP1+/+ and SFRP1−/− females (n = 6 animals/genotype). Real-time PCR experiments were carried out in duplicate. The results shown represent
experiments performed in duplicate and normalized to the amplification of β-actin mRNA. Bars represent mean ± SEM of the fold change with
respect to vehicle treated cells. *p < 0.05, **p < 0.01 (significantly different from vehicle treated cells using student’s t-test).
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life span [54,55]. Therefore the potential effect of SFRP1
loss on stem cell number and mammosphere formation
is critical to breast tumorigenesis.
Conclusions
The work described herein clearly demonstrate that
SFRP1−/− mice exhibit precocious mammary gland side
branching with clear lobulo-alveolar development, which
normally only occurs in hormonally stimulated mid-
pregnant wt mammary glands. These changes may be
partially explained by alterations in the expression of
genes critical for mammary gland development and by
an increase in the number of mammosphere forming
cells. Previously, it has been demonstrated thatsuppression of SFRP1 expression is an early change in
human premalignant breast lesions [21]. Taken together,
our study indicates that the SFRP1 gene is critical for
maintaining proper mammary gland development, that
reduced levels of SFRP1 results in hyperplastic lesions,
and its loss may be a critical event in cancer initiation.
Therefore, caution should be exercised in the potential
use of SFRP1 inhibitors for the treatment of osteroporo-
sis until the effects of such inhibition on breast tumori-
genesis are fully elucidated.
Methods
Animals
All procedures were performed in accordance with the
NIH guidelines for the ethical treatment of animals and
Figure 5 Loss of SFRP1 promotes the expansion of
mammosphere initiating cells. Mouse mammary epithelial cells
from SFRP1+/+ and SFRP1-/- (n = 4 animals/genotype) were seeded
on low attachment plates and allowed to grow for 21 days. In vitro
quantification of mammpospheres formed by cells as described. Bars
represent mean ± SEM number of spheres formed/20,000 seeded
cells from 3 separate experiments. *p < 0.05 (significantly different
from SFRP1+/+ MMEC cells using student’s t-test).
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tional AnimalCare and Use Committee before initiating
these studies. Female 129/C57Blk6 mice (n = 6) were in-
dividually housed in plastic cages with food and water
provided continuously, and maintained on a 12:12 light
cycle.
Whole-mounts and carmine stain of mammary glands
Mice were euthanized with carbon dioxide and fifth in-
guinal mammary glands were excised from 5 wk virgin, 10
wk virgin, pregnant day 8, and pregnant day 15 animals,
spread on microscope slides, and fixed overnight in metha-
carn (60% methanol, 30% chloroform, 10% acetic acid).
The fixed glands were washed in 70% ethanol for 15 min,
rinsed in water for 5 min, and stained overnight at 4°C in
carmine alum stain (1 g carmine and 2.5 g aluminum po-
tassium sulfate in 500 ml water). The glands were then
dehydrated progressively in 70%-95%-100% ethanol,
cleared in xylene for 1 hr, and mounted on slides with
Cytoseal™XYL mounting medium (Richard-Allan Scien-
tific). Mammary whole mounts where photographed using
an Olympus BX41 light microscope using SPOTSOFT-
WARE (Diagnostic Instruments, Inc, Sterling Heights, MI).
Histomorphology
Fourth or sixth inguinal mammary glands from 5 wk vir-
gin, 10 wk virgin, 23 wk virgin, pregnant day 8, and
pregnant day 15 animals (n = 6 animals/genotype) were
formalin-fixed and paraffin-embedded. Tissue sections
were cut on a Leica microtome at a thickness of 4 μm
on Superfrost-plus slides, and stained with hematoxylin
and eosin (H&E) per standard protocol. Briefly, slides
were dried in a microwave for 1 min and then at 62°C
for 15 minutes. Slides were subsequently de-paraffinizedwith xylene 3X, cleared with graded ETOH (100% X2,
95%, 70%), and rinsed in dH2O. Sections were stained
for 3 minutes in Mayer’s hematoxylin, washed with gla-
cial acetic acid water for 15 sec, and then ammonia
water to blue, and stained with eosin. Finally, slides were
dehydrated in ETOH and xylene before manual cover-
slipping. Stained images were captured with an Olympus
BX41 light microscope using SPOTSOFTWARE.
Ex vivo tissue culture and immunohistochemistry
Mice were euthanized with carbon dioxide and fourth
inguinal mammary glands were excised (n = 6 animals/
genotype). The tissue was aseptically minced and for
each genotype, a representation from all 6 animals was
placed on 2 different Surgifoam gelatin sponges (Ferro-
san, Sueborg, Denmark) in 60 mm tissue culture dishes
containing 5 mL of control or Wnt3a medium prepared
as described [18]. Explant cultures were maintained for
24 hours in 5% CO2 air and subsequently formalin-fixed
and paraffin-embedded.
Immunohistochemistry (IHC) was performed on a
DakoCytomation autostainer using the Envision HRP
Detection system (Dako, Carpinteria, CA). Each mam-
mary tissue block was sectioned at 4 μm on a graded
slide, deparaffinized in xylene, rehydrated in graded
ethanols, and rinsed in Tris-phosphate-buffered saline
(TBS). Heat induced antigen retrieval was performed in
a microwave at 98°C in 0.01 M citrate buffer. After cool-
ing for 20 minutes, sections were rinsed in TBS and sub-
jected to the primary rabbit polyclonal anti-Axin2
antibody (1:100, Abcam, ab32197) for 45 minutes.
Immunoreactivity was visualized by incubation with
chromogen diaminobenzidine (DAB) for 5 minutes. Tis-
sue sections were counterstained with hematoxylin,
dehydrated through graded ethanols and xylene, and
cover-slipped. Images were captured with an Olympus
BX41 light microscope using SPOTSOFTWARE.
RNA isolation and real-time PCR analysis
Total RNA was extracted from the sixth inguinal mam-
mary glands of 5 week old animals using an acid-phenol
extraction procedure [56], according to the manufac-
turer’s instructions (Trizol, Invitrogen, Carlsbad, CA).
Relative levels of the mRNA expression of target genes
was determined by quantitative real-time PCR using the
M3005P™ real-time PCR system (Stratagene, La Jolla,
CA) and all values were normalized to the amplification
of β-Actin. The PCR primer sequences are described in
Table 1. The assays were performed using the 1-Step
BrilliantW SYBRIIW Green QRT-PCR Master Mix Kit
(Stratagene) containing 200 nM forward primer, 200 nM
reverse primer, and 100 ng total RNA. The conditions
for cDNA synthesis and target mRNA amplification
were performed as follows: 1 cycle of 50°C for 30 min;1









Rspo1 forward 5’- CGACATGAACAAATGCATCA -3’
reverse 5’- CTCCTGACACTTGGTGCAGA -3’
Rspo2 forward 5’- GCCCATCAGGGTATTATGGA -3’
reverse 5’- TCACAGTTTTCTATTCTGCATCG -3’
β-Actin forward 5’- CTAAGGCCAACCGTGAAAAG -3’
reverse 5’- ACCAGAGGCATACAGGGACA -3’
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30 s, 55°C for 1 min, and 72°C for 30 s.Primary mouse mammary cell isolation and
mammosphere culture
Eight 8–10 week old virgin mice were euthanized with
carbon dioxide (4 SFRP1+/+ and 4 SFRP1−/−) and fourth
mammary glands were harvested, minced, and finally
dissociated in DMEM:F12 (Sigma, St. Louis, MO) sup-
plemented with 5 % fetal bovine serum (Gibco, Paisleley,
UK), 2 mg/ml collagenase (Worthington Biochemicals,
Freehold, NJ), 100u/ml hyaluronidase (Sigma), 100u/ml
pen/strep (Gibco) and 100 μg/ml gentamicin (Gibco) for
6 hours. The cell pellet was collected and further disso-
ciated with 1mlpre-warmed 0.05% Trypsin-EDTA
(Gibco) and 200μl1mg/ml Dnase I (Roche, Mannheim,
Germany). Cell suspensions were sieved through a
40 μm cell strainer to obtain single cell suspensions. Pri-
mary single cells were seeded onto ultra-low attachment
dishes (Corning, Corning, NY) at a density of 20,000 vi-
able cells/ml. Cells were grown in a serum-free mam-
mary growth medium (EpiCultWB for Mouse Mammary
Epithelial Cell Culture, Vancouver, BC) supplemented
with 10ng/ml EGF (Sigma), 10 ng/ml FGF (Sigma),
4 μg/ml heparin, 100u/ml pen/strep (Gibco) and 100 μg/ml
gentamicin (Gibco) [50]. On day 21, the total num-
ber of mammospheres was quantified by counting
spheres that were at least 100 μm in size. Images of
mammosphere formation were captured with a Nikon
Eclipse TE2000-Uusing Metaview™ software.
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